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Background: Impairments in skeletal muscle oxidative phenotype (OXPHEN) have been linked to the development
of insulin resistance, metabolic inﬂexibility and progression of the metabolic syndrome and have been associated
with progressive disability in diseases associated with chronic systemic inﬂammation. We previously showed that
the inﬂammatory cytokine tumour necrosis factor-α (TNF-α) directly impairs muscle OXPHEN but underlyingmolec-
ular mechanisms remained unknown. Interestingly, the inﬂammatory signalling pathway classical nuclear factor-κB
(NF-κB) is activated in muscle in abovementioned disorders. Therefore, we hypothesised that muscle activation of
classical NF-κB signalling is sufﬁcient and required for inﬂammation-induced impairment of muscle OXPHEN.
Methods:Myotubes frommouse and humanmuscle cell lines were subjected to activation or blockade of the classical
NF-κB pathway. In addition, wild-type and MISR (muscle-speciﬁc inhibition of classical NF-κB) mice were injected
intra-muscularly with TNF-α. Markers and key regulators of muscle OXPHEN were investigated.
Results: Classical NF-κB activation diminished expression of oxidative phosphorylation (OXPHOS) sub-units, slow
myosin heavy chain expression, activity of mitochondrial enzymes and potently reduced intra-cellular ATP levels.
Accordingly, PGC-1/PPAR/NRF-1/Tfam signalling, the main pathway controlling muscle OXPHEN, was impaired
upon classical NF-κB activation which required intact p65 trans-activation domains and depended on de novo
gene transcription. Unlike wild-type myotubes, IκBα-SR myotubes (blocked classical NF-κB signalling) were re-
fractory to TNF-α-induced impairments in OXPHEN and its regulation by the PGC-1/PPAR/NRF-1/Tfam cascade.
In line with in vitro data, NF-κB blockade in vivo abrogated TNF-α-induced reductions in PGC-1α expression.
Conclusion: Classical NF-κB activation impairs skeletal muscle OXPHEN.© 2013 Elsevier B.V. All rights reserved.viral; CHF, chronic heart failure;
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Loss of skeletal muscle oxidative phenotype (OXPHEN) is observed
in many diseases associated with chronic low-grade systemic inﬂamma-
tion including chronic obstructive pulmonary disease (COPD), chronic
heart failure (CHF) and type II diabetes mellitus (T2DM) [1–8]. OXPHEN
is deﬁned as the collective of intrinsic cell-speciﬁc features determining
fatigue resistance and capacity for mitochondrial substrate oxidation.
Observed impairments in muscle OXPHEN in abovementioned disor-
ders include a ﬁbre-type shift from type I ﬁbres towardsmore glycolytic
type II ﬁbres, a reduction in mitochondrial content, reduced activity
levels of mitochondrial metabolic enzymes and a diminished muscle
ATP content [1,3,9–11]. Illustrative of its signiﬁcance in chronic disease
prevention and progression, a disturbed muscle OXPHEN has been
linked to the development of insulin resistance, metabolic inﬂexibility
and progression of the metabolic syndrome and has been associated
with progressive disability and a reduced quality of life in chronic
disorders [12–15]. Importantly, impairments in muscle OXPHEN in
chronic disease reﬂect pathological mechanisms beyond physical
inactivity of which inﬂammation has been explored as a putative
trigger [16].
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master intra-cellular signalling pathway controlling skeletal muscle
OXPHEN [17]. The 2 main isoforms, PGC-1α and PGC-1β, serve as key
co-activator molecules orchestrating a transcriptional programme that
directs muscle ﬁbre-type composition aswell asmitochondrial capacity
towards an improved OXPHEN [18,19]. This programme includes
co-activation of nuclear respiratory factor 1 (NRF-1)-driven transcrip-
tion ofmitochondrial transcription factor A (Tfam) genewhich is essen-
tial for mitochondrial biogenesis. In addition, PGC-1 isoforms facilitate
peroxisome proliferator-activated receptor (PPAR) transcriptional
activity of which the PPAR-α and PPAR-δ isoforms regulate mitochon-
drial substrate oxidation processes and muscle ﬁbre-type composition
[19]. Reduced expression levels of constituents of the PGC-1/PPAR/
NRF-1/Tfam signalling axis have been shown in skeletal muscle of
both COPD and T2DM patients and may well underlie impairments in
muscle OXPHEN [16,20–22].
Low-grade systemic inﬂammation is a common denominator of
many chronic diseases [4,23,24]. We previously showed that, in
COPD, circulating and muscle levels of the pro-inﬂammatory cytokine
tumour necrosis factorα (TNF-α) and its receptors are inversely associ-
ated with PGC-1/PPAR and oxidative gene mRNA expression levels in
muscle [16,20]. Furthermore, in vitro, we showed that TNF-α directly
impairs the OXPHEN of cultured muscle cells. Collectively this suggests
a role for TNF-α in the (de)regulation of muscle OXPHEN [16].
The ubiquitously expressed classical nuclear factor kappa B
(NF-κB) pathway is the main intra-cellular signalling cascade activated
by inﬂammatory cytokines such as TNF-α. Under normal physiological
conditions, the NF-κB sub-unit RelA/p65 is maintained primarily in
the cytoplasm bound to an IκB repressor molecule. Active classical
NF-κB signalling is triggered when inﬂammatory stimuli, such as
TNF-α or interleukin 1 β (IL-1β), initiate the rapid phosphorylation
and degradation of IκBα through IKK-β kinase activity. This liberates
p65 to move into the nucleus and initiate transcription of NF-κB target
genes [25]. Increased activation of the classical NF-κB pathway inmuscle
has been shown in COPD, CHF, and T2DM [26–30]. However, whether or
not classical NF-κB signalling is causally involved in the (de)regulation
of skeletal muscle OXPHEN in these disorders is unknown. We
hypothesised that activation of classical NF-κB signalling impairs skeletal
muscle OXPHEN and its regulation by the PGC-1/PPAR/NRF-1/Tfam
signalling cascade. To address this, we modulated classical NF-κB
signalling, in absence or presence of inﬂammatory cytokines, in
culturedmuscle cells and inmousemuscle tissue in vivo and investigated
the impact on muscle OXPHEN and its molecular regulation.
2. Materials and methods
2.1. Cell culture
The murine C2C12 skeletal muscle cell line was obtained from the
American Type Culture Collection (ATCC CRL1772; Manassas, VA, USA).
The stable C2C12 NF-κB transcriptional activity reporter cell line was
constructed as described previously [31] and C2C12-IκBα-SR cells
(displaying blocked classical NF-κB signalling) were kindly provided by
Dr. Guttridge (Ohio State University, OH, USA). C2C12 myoblasts were
cultured anddifferentiated intomaturemulti-nucleatedmyotubes as de-
scribed previously [31]. Mouse primary muscle cells were derived from
hind and forelimbs of neonatal C57/BL6 mice [32] and were cultured
according to the same protocol as the C2C12 cell line. Immortalised
human muscle cells were provided by Dr. De la Garza-Rodea (Leiden
University, The Netherlands). Additional detail regarding culture condi-
tions is provided in the online resource.
2.2. Animals
Wild-typemale C57/BL6micewere purchased from Jackson Laborato-
ries (Bar Harbor, ME, USA). MISR (muscle-speciﬁc IκBα Super-Repressor)animals were kindly provided by Dr. S. Shoelson (Joslin Diabetes Center,
MA, USA). All animals were housed in a temperature-controlled room
on a 12:12 h light-dark cycle with food pellets and water provided ad
libitum. All procedures were performed with approval of the University's
Institutional Animal Care andUse Committee andwere in coherencewith
the EU Directive 2010/63/EU regarding animal experiments. Animals re-
ceived either intra-muscular (IM) injections of phosphate buffered saline
(PBS) (50 μL) or murine TNF-α (40 μg/kg in 50 μL PBS) delivered to the
gastrocnemius of both hind limbs with a 30 gauge needle (Ultra-Fine II,
Becton Dickinson, NJ, USA) while lightly anesthetised. Seven hours after
IM injection, mice were sacriﬁced by halothane overdose. Gastrocnemius
muscleswere collectedusing standardised dissectionmethods, cleanedof
excess fat and connective tissue, snap frozen in liquid nitrogen and stored
at−80 °C.
2.3. Chemicals and reagents
TNF-α (Calbiochem, Nottingham, United Kingdom) and interleukin
1β (IL-1β) (Calbiochem) were dissolved in 0.1% bovine serum albumin
(BSA) which also served as a vehicle control (0.005% ﬁnal concentra-
tion) to a stock of 200 ng/ml. Actinomycin D (Sigma Aldrich, Saint
Louis, MO, USA) was dissolved in dimethyl sulfoxide (DMSO) to a
stock concentration of 10 mg/ml. Rosiglitazone-maleate (Alexis Bio-
chemicals, Lausen, Switzerland), GW501516 (Alexis Biochemicals)
and WY-14643 (Biomol, Plymouth Meeting, PA, USA) were all
dissolved in DMSO to a stock concentration of 75 mM, 1 mM and
50 mM respectively. Pre-made adenoviral (AV) constructs (AV-CMV-
IKK-β and AV-CMV-GFP) were purchased from Vector Biolabs
(Philadelphia, USA). Viral expression constructs were dissolved in
Dulbecco's modiﬁed Eagle medium (DMEM) with 2% BSA and 2.5%
Glycerol (1 × 1010 PFU/ml) and further diluted in sterile Hank's
balanced salt solution (HBSS) (Invitrogen, Leusden, the Netherlands)
to a stock concentration of 2 × 108 PFU/ml. A ﬁnal concentration of
2 × 107 PFU/mlwas added to fully differentiatedmyotubes. SiRNA con-
structs targeting PGC-1α and scrambled control siRNA constructs were
purchased from Invitrogen.
2.4. Western blot and quantitative PCR (Q-PCR)
Details regarding preparation of whole-cell lysates and western
blotting procedures as well as information regarding RNA isolation,
cDNA synthesis and Q-PCR can be found in the online resource.
2.5. ATP assay
Myotubes were washed in ice-cold PBS and harvested in 200 μl
HCLO4 by scraping with rubber policemen. Lysates were incubated on
ice for 10 min and subsequently centrifuged for 10 min, 14000 rpm
at 4 ○C. Supernatant was removed and 8 μl 5 M K2CO3 was added.
Pellets were used to determine total protein content according to
manufacturer's instructions (Bio-Rad,Hercules, CA, USA). Nucleotide pro-
ﬁles were determined by ion exchange high-performance liquid chroma-
tography (HPLC) using a Whatman Partisphere SAX 4.6 × 125 mm
column (5-μmparticles) and aWhatman 10 × 2.5 mmAX guard column
(Whatman Inc, ME, USA). The buffers used were: 9 mM NH4H2PO4,
pH 3.5 (buffer A) and 325 mM NH4H2PO4,500 mM KCl, pH 4.4 (buffer
B). Nucleotides were eluted with a gradient from 100% buffer A to 90%
buffer B in 60 min at a ﬂow rate of 1 ml/min.
2.6. Enzyme activity assays
Activity of β-hydroxyacyl CoA dehydrogenase (HAD) (EC 1.1.1.35)
and citrate synthase (CS) (EC2.3.3.1) was measured as described previ-
ously [33]. Enzyme activity levels weremeasured at 37 °C and at PH 7.3
(HADH) or PH 8.0 (CS) and were corrected for total protein content
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nation assay (Bio-Rad).
2.7. Electron microscopy
For determination of ultrastructural mitochondrial morphology,
C2C12myotubes cultured in 35 mmdisheswereﬁxed in 2.5% glutaralde-
hyde in 0.1 M phosphate buffer (pH 7.4). Postﬁxation was performed in
1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4) supplemented
with 1.5% potassium ferrocyanide. The samples were then dehydrated
and embedded in epon. Ultrathin sections were examined using a Philips
CM100 electron microscope.
2.8. Transfections and plasmids
For the assessment of NF-κB transcriptional activity, C2C12 cells
were stably transfected with a 6κB-TK luciferase plasmid (NF-κB re-
porter) as previously described [31]. For transient transfections, C2C12
cells were grown to be 50% conﬂuent and transfected by nanofectin
according to manufacturer's instructions (PAA, Pasching, Austria). For
assessment of general PPAR-dependent transcriptional activity, C2C12
myoblasts were transfected with a human CPT-1B promoter (HCBP)
luciferase reporter construct which was a kind gift from Dr. M. van
Bilsen (Maastricht University, The Netherlands). For assessment of spe-
ciﬁc PPAR transcriptional activity, the pM1-hPPAR-α (LBD)/Gal4(DBD),
pM1-hPPAR-δ(LBD)/Gal4(DBD), pM1-PPAR-γ(LBD)/Gal4(DBD) and
UASx4luc reporter constructs were kindly provided by Dr. Kristiansen
(University of Southern Denmark, Odense, Denmark) and are previously
described [34]. To investigate the involvement of classical NF-κB sig-
nalling, the following expression plasmids were transiently trans-
fected into C2C12 myoblasts according to the same protocol:
IκBα-SR (pSFFV-NEO-IκBα-SR) (constitutively expressed under
control of the SFFV-LTR); kind gift from Dr. Rosa Ten (Mayo Clinic,
Rochester, MN, USA), p65 wild-type (p65 WT), IKK-β kinase-dead
(IKK-β KD) and constitutive active IKK-β (c.a. IKK-β); all kind
gifts from Dr. Michael Karin (University of California, San Diego,
La Jolla, CA, USA). p65 mutants with 1 (p65-534), 2 (p65-521),
or 3 (p65-313) deleted trans-activation domains were kindly provided
by Dr. D. Guttridge (Ohio State University, OH, USA). For assessment of
Tfam promoter activity and NRF-1 transcriptional activity, cells were
transfected with mTFA-RC4wt/PGL3 or p4xNRF-1LUC reporter con-
struct [35,36]. The β-MyHC (I, slow) promoter reporter construct was
kindly provided by Dr. M. Sandri (University of Padova, Italy). The
PcDNA3.1 empty vector was used as an empty vector control when ap-
propriate. All transient transfections were corrected for β-galactosidase
(β-Gal) activity. Details regarding reporter assays are provided in the
online resource.
2.9. Electrophoretic mobility shift assay (EMSA)
Details regarding preparation of nuclear extracts are provided in the
online resource. NF-κBDNAbinding activitywas assessed in nuclear ex-
tracts by analysis of complexes binding to an oligonucleotide containing
a κB consensus sequence (Santa Cruz, Santa Cruz, CA, USA). Twomicro-
grams of nuclear protein was used per binding reaction and protein–
DNA complexes were resolved on a 5% polyacrylamide gel in 0.25×
Tris–borate–EDTA buffer at 120 V for 2 h. Gels were dried and exposed
toﬁlm (X-Omat Blue XB-1, Kodak, Rochester, NY, USA). Supershift reac-
tions were performed by pre-incubation of the nuclear extracts with an
antibody speciﬁc to the p65 subunit of NF-κB (Santa Cruz).
2.10. Statistics
Data were analysed according to the guidelines of Altman et al.
using SPSS (SPSS Inc., Chicago, IL, USA). Non-parametric tests andunpaired t-tests were used when appropriate. Data are represented as
the mean ± SD. A p-value of less than 0.05 was considered to be
signiﬁcant.
3. Results
3.1. Classical NF-κB activation is sufﬁcient to reduce expression and function
of mitochondrial proteins
To investigate whether a reduction in protein content of mitochon-
drial oxidative phosphorylation (OXPHOS) complexes, as observed in
response to TNF-α [16], is common to classical NF-κB activation and is
associated with correspondingly decreased mRNA expression levels,
C2C12 myotubes were stimulated with IL-1β or subjected to IKK-β
over-expression. OXPHOS protein as well as mRNA levels were
investigated.
IL-1β-induced NF-κB activation was conﬁrmed (Fig. S1A) and
over-time not only decreased OXPHOS sub-unit protein levels but
also signiﬁcantly reduced mRNA levels of the respective OXPHOS
complexes (Fig. 1a, b). Similarly, genetic NF-κB activation by adenoviral
(AV) delivery of IKK-β (Fig. S1B, C) decreased bothOXPHOS protein and
mRNA levels (Fig. 1c, d). Furthermore, besides reducing OXPHOS
expression levels, genetic NF-κB activation in C2C12 myotubes
was sufﬁcient to reduce activity levels of mitochondrial enzymes
involved in substrate oxidation (citrate synthase: CS; Krebs cycle and
β-hydroxyacyl CoA dehydrogenase: HAD; fatty acid β-oxidation)
(Fig. 1e, f).
3.2. Classical NF-κB activation is required for TNF-α-induced reductions
in expression of mitochondrial proteins
Similar to IL-1β and AV-IKK-β, TNF-α-induced NF-κB activation
(Fig. S1A) decreased OXPHOS sub-unit mRNA levels, not only in
C2C12 myotubes but also in mouse- and human primary myotubes
(Fig. 2a–f). In contrast to its effects on wild-type C2C12 myotubes,
TNF-α failed to reduce OXPHOS mRNA and protein expression in
C2C12 myotubes (Fig. 2d–g) in which classical NF-κB activation was
effectively blocked (IκBα-SR C2C12) (Fig. S1D–F). Moreover, TNF-α
stimulation of wild-type C2C12 myotubes reduced cellular ATP con-
tent to 50% of control which was completely abrogated in IκBα-SR
myotubes (Fig. 2h). In contrast, TNF-α-induced reductions in HAD
enzyme activity were not attenuated in IκBα-SR C2C12 myotubes
(Fig. 2i). Although basal HAD activity was increased in IκBα-SR
myotubes compared to WT myotubes (Fig. 2i), basal OXPHOS
sub-unit protein or mRNA expression levels were similar in both cell
lines (Fig. S2A, B). In addition, in contrast to IKK-β over-expression,
TNF-α stimulation of wild-type C2C12 myotubes failed to affect CS ac-
tivity levels (data not shown).
3.3. Classical NF-κB activation perturbs mitochondrial morphology
Considering the aberrant expression and activity of essential mito-
chondrial proteins in conditions of classical NF-κB activation,mitochon-
drial morphology was assessed in C2C12 myotubes. In response to
TNF-α-induced NF-κB activation, mitochondria appeared swollen
and less elongated compared to mitochondria from vehicle-treated
myotubes (Fig. 3a). As mitochondrial ﬁssion and fusion genes are
key regulators of mitochondrial dynamics, expression levels of these
markers were investigated in response to classical NF-κB activation.
TNF-α signiﬁcantly reduced mRNA expression levels of mitochondrial
fusion (mfn-1, mfn-2 and Opa1) and ﬁssion genes (MTP18 and FIS1)
in C2C12 myotubes (Fig. 3b, c). Similar ﬁndings (with exception of de-
creased Opa1 mRNA levels) were found in mouse primary myotubes
in response to TNF-α (Fig. 3d). In addition, IL-1β stimulation as well
as AV-IKK-β delivery to wild-type C2C12 myotubes similarly decreased
selected fusion and ﬁssion gene mRNA expression levels (Fig. 3e, f). In
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Fig. 1. Classical NF-κB activation impairs expression and function of mitochondrial proteins C2C12 myoblasts were differentiated for 5 days in differentiation medium into fully
mature myotubes. a, b) Myotubes were stimulated with vehicle (bovine serum albumin; control) or interleukin-1β (IL-1β; 10 ng/ml) for 120 h (a) or for the indicated time (b).
c–f) Myotubes were infected with an adenoviral (AV) construct expressing IKK-β or an AV-GFP construct as control for 120 h (c, e, f) or for the indicated time (d). Cells were
harvested at the indicated time-points and oxidative phosphorylation (OXPHOS) sub-unit mRNA and protein expression and β-hydroxy-acyl CoA dehydrogenase (HAD) and citrate
synthase (CS) enzyme activities were determined. Western blots were corrected for total protein and GAPDH was used as a loading control. Gene expression data were corrected by
using a GeNorm normalisation factor calculated from the expression of 4 housekeeping genes (cyclophilinA, β2-microglobuline, hypoxanthine-guanine phosphoribosyltransferase
and glyceraldehyde-3-phosphate dehydrogenase). Enzyme activity levels were corrected for total protein content. Values are expressed as mean ± SD from triplicate samples (experi-
ments n = 3). Signiﬁcance compared to control: * p ≤ 0.05, # p ≤ 0.1.
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transcript levels increased rather than decreased in response to TNF-α
stimulation in IκBα-SR myotubes (Fig. 3b, c).
3.4. Activation of classical NF-κB signalling impairs slow MyHC expression
IL-1β stimulation of C2C12 myotubes decreased MyHC slow pro-
tein and MyHC I mRNA levels while MyHC fast protein and MyHC IIxmRNA levels were unaffected (Fig. 4a–c). Similarly, AV-IKK-β deliv-
ery to C2C12 myotubes potently reduced MyHC slow protein and
MyHC I mRNA levels without altering MyHC fast protein or MyHC
IIx mRNA abundance (Fig. 4d–g). In line with these data, a constitu-
tive active form of IKK-β (IKK-β c.a.) was sufﬁcient to diminish
MyHC I promoter activation, while transfection of a kinase-dead iso-
form of IKK-β (IKK-β KD) had no signiﬁcant effect (Fig. 4h). Impor-
tantly, we veriﬁed that both inﬂammatory cytokine-induced and
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Fig. 2. Classical NF-κB activation is required for TNF-α-induced reductions in expression of mitochondrial proteins. a–c) Mouse and human primary myoblasts were differentiated
for 5 days in differentiation medium into fully mature myotubes. Myotubes were subsequently stimulated with vehicle (bovine serum albumin; control) or tumour necrosis factor
α (TNF-α; 10 ng/ml) for the indicated time and oxidative phosphorylation (OXPHOS) sub-unit mRNA expression was determined by Q-PCR. d–i) Wild-type (WT) C2C12 or
C2C12-IκBα-super-repressor (SR) myoblasts were differentiated for 5 days in differentiation medium into fully mature myotubes. Myotubes were stimulated with vehicle (bovine
serum albumin; control) or TNF-α (10 ng/ml) for 120 h or for the indicated times and OXPHOS sub-unit mRNA and protein expression as well as β-hydroxy-acyl CoA dehydrogenase
(HAD) enzyme activity and ATP content were determined.Western blots were corrected for total protein and GAPDHwas used as a loading control. Gene expression datawere corrected
by using a GeNormnormalisation factor calculated from the expression of 4 housekeeping genes (cyclophilinA,β2-microglobuline, hypoxanthine-guanine phosphoribosyltransferase and
glyceraldehyde-3-phosphate dehydrogenase). Enzyme activity levels and ATP content were corrected for total protein content. Values are expressed as mean ± SD from triplicate samples
(experiments n = 3). Signiﬁcance compared to control: * p ≤ 0.05, # p ≤ 0.1.
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levels of type I, slow MyHC in mouse- and human primary myotubes
(Fig. S3A–C).In wild-type C2C12 myotubes, TNF-α-induced reductions in
MyHC I mRNA and MyHC slow protein became apparent after 24 h
and 48 h of TNF-α stimulation respectively (Fig. S3D, E and Fig. 4j).
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Fig. 3. Classical NF-κB activation perturbs mitochondrial morphology. a) C2C12 myoblasts were differentiated for 5 days in differentiation medium into fully mature myotubes.
Myotubes were subsequently stimulated with vehicle (bovine serum albumin; control) or tumour necrosis factor α (TNF-α; 10 ng/ml) for 120 h and transmission electron microscopy
was applied to visualise mitochondrial morphology. b, c)Wild-type (WT) C2C12 or C2C12-IκBα-super-repressor (SR)myoblasts were differentiated for 5 days in differentiationmedium
fully mature myotubes. Myotubes were stimulated with vehicle (bovine serum albumin; control) or TNF-α (10 ng/ml) for the indicated times. mRNA levels of mitochondrial ﬁssion and
fusion genes were determined by Q-PCR. d) Mouse primary myoblasts were differentiated into mature myotubes and treated with vehicle (bovine serum albumin; control) or TNF-α
(10 ng/ml) for 72 h. mRNA levels of mitochondrial ﬁssion and fusion genes were determined by Q-PCR. e, f) C2C12 myoblasts were differentiated for 5 days in differentiation medium
into fully mature myotubes. Myotubes were subsequently stimulated with vehicle (bovine serum albumin; control) or interleukin-1β (IL-1β; 10 ng/ml) or infected with an adenoviral
(AV) construct expressing IKK-β or an AV-GFP construct as control for the indicated time. Gene expression data were corrected by using a GeNorm normalisation factor calculated
from the expression of 4 housekeeping genes (cyclophilinA, β2-microglobuline, hypoxanthine-guanine phosphoribosyltransferase and glyceraldehyde-3-phosphate dehydrogenase).
Values are expressed as mean ± SD from triplicate samples (experiments n = 3). Signiﬁcance compared to control: * p ≤ 0.05, # p ≤ 0.1.
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Fig. 4. Classical NF-κB activation impairs slow, type I MyHC expression. a–g) C2C12myoblasts were differentiated for 5 days in differentiationmedium into fully mature myotubes. Myotubes
were subsequently stimulatedwith vehicle (bovine serum albumin; control) or interleukin-1β (IL-1β; 10 ng/ml) or infectedwith an adenoviral (AV) construct expressing IKK-β or an AV-GFP
construct as control for 120 h or the indicated time.MyHC slow andMyHC fast protein andMyHC I and IIxmRNA levelswere determined byWestern blotting andQ-PCR respectively. h) C2C12
myoblastswere transiently transfectedwith amyosin I slowpromoter reporter construct. Simultaneously, plasmids encoding empty vector (PcDNA3.1) or plasmids encoding constitutive active
IKK-β (c.a. IKK-β) or a kinase-dead IKK-β isoform (IKK-β KD) were co-transfected. Cells were stimulated with TNF-α (10 ng/ml) or vehicle (bovine serum albumin). Twenty-four hours after
transfection cells were lysed, luciferase activity was determined and normalised for β-galactosidase activity. i, j) Wild-type (WT) C2C12 or C2C12-IκBα-super-repressor (SR) myoblasts were
differentiated for 5 days in differentiation medium into fully mature myotubes. Myotubes were stimulated with vehicle (bovine serum albumin; control) or TNF-α (10 ng/ml) for
120 h or the indicated time. MyHC slow and MyHC fast protein and MyHC I mRNA levels were determined by Western blotting and Q-PCR respectively. k) C2C12 myoblasts
were transiently transfected with a myosin slow, I promoter reporter construct and PcDNA3.1 as an empty vector or a plasmid expressing the IκBα-super repressor (IκBα-SR).
Twenty-four hours post-transfection cells were treated with vehicle (bovine serum albumin; control) or TNF-α (10 ng/ml) for 24 h. Subsequently, cells were lysed, luciferase activity was
determined and normalised for β-galactosidase activity. Gene expression data were corrected by using a GeNorm normalisation factor calculated from the expression of 4 housekeeping
genes (cyclophilinA, β2-microglobuline, hypoxanthine-guanine phosphoribosyltransferase and glyceraldehyde-3-phosphate dehydrogenase).Western blots were corrected for total protein
and GAPDH was used as a loading control. Values are expressed as mean ± SD from triplicate samples (experiments n = 3). Signiﬁcance compared to control: * p ≤ 0.05.
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times were applied (data not shown). Compared to wild-type cells,
TNF-α-induced reductions in MyHC slow protein and MyHC I mRNA
levels were completely abrogated in C2C12 myotubes with blockedclassical NF-κB signalling (Fig. 4i, j). In line with protein and mRNA
data, TNF-α reduced MyHC type I promoter activity which was
prevented upon transient expression of non-degradable mutant
SR-IκBα protein (Fig. 4k).
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phenotype
Multiple molecules have been implicated in the regulation of skeletal
muscle OXPHEN [19,37]. As depicted in Fig. 5a, TNF-α signiﬁcantly
reduced mRNA expression levels of PGC-1α, PGC-1β, PPAR-α anda
c
d
b
e f
g
0Tfam while expression levels of other known regulators of muscle
OXPHEN (NRF-1, PPAR-δ, NRF-2α, ERR-α and SIRT-1) were unaltered.
As shown in Fig. 5b, C, activation of classical NF-κB signalling by
TNF-α or transient over-expression of c.a. IKK-β in C2C12 cells potently
reduced Tfam promoter activity as well as NRF-1 transcriptional
activity, both of which depend on PGC-1 mediated co-activation
1321A.H.V. Remels et al. / Biochimica et Biophysica Acta 1832 (2013) 1313–1325[38]. Transfection of kinase-dead IKK-β on the other hand resulted
in signiﬁcant sparing of reporter activity compared to transfection
of the IKK-β c.a. isoform. In addition, TNF-α reduced general PPAR
transcriptional activity as well as basal and agonist-induced tran-
scriptional activity of individual PPAR isoforms (Fig. 5d, g and Fig.
S4A). Similar to the observations using Tfam and NRF-1 reporter con-
structs, over-expression of c.a. IKK-βdiminished PPAR transcriptional ac-
tivity which was signiﬁcantly attenuated when a kinase-dead IKK-β
isoformwas over-expressed (Fig. 5d). As p65 is the DNA-binding protein
down-stream of IKK-β in the classical NF-κB pathway [25], we next in-
vestigated whether p65 directly interferes with the regulation of muscle
OXPHEN. As shown in Fig. 5e, f, over-expression of wild-type p65 po-
tently decreased PPAR-α and PPAR-γ transcriptional activity and, inter-
estingly, serial deletion of 1, 2 or all 3 p65 trans-activation domains
increasingly restored PPAR transcriptional activity (Fig. 5e, f). TNF-α-
induced reductions in transcriptional activity of the speciﬁc PPAR
isoforms were abrogated when classical NF-κB activity was blocked by
over-expression of the IκBα-SR construct (Fig. 5g).3.6. Classical NF-κB activation reduces PGC-1 expression
TNF-α decreased both PGC-1α and PGC-1β mRNA levels
over-time in mouse primary myotubes as it did in C2C12 myotubes
(Fig. 6a, b). A more detailed time-course investigation revealed that
TNF-α-induced reductions in PGC-1α mRNA in C2C12 myotubes be-
came apparent after 8 h and persisted over time while reductions in
PGC-1β mRNA levels only occurred after 72 h of TNF-α exposure
(Fig. 6c, d). Moreover, TNF-α-induced reductions in PGC-1α but not
PGC-1β expression levels consistently depended on intact classical
NF-κB signalling (Fig. 6c, d). In order to verify whether TNF-α reduces
muscle PGC-1α mRNA levels in vivo and whether this depended on
classical NF-κB activation, we injected WTmice and MISR mice (genet-
ically blocked NF-κB signalling by stable muscle-speciﬁc expression of
the IκBα-SR construct) intra-muscularly with TNF-α. TNF-α-induced
p65 DNA binding and inﬂammatory gene expression was quantiﬁed
7 h after intra-muscular injection and found to be abrogated in MISR
mice compared to WT animals (Fig. S5A, B). Injection of TNF-α signiﬁ-
cantly decreased PGC-1α, not PGC-1β (data not shown), mRNA levels
inWT animals but not in MISRmice (Fig. 6e). In addition, to investigate
whether activation of classical NF-κB is sufﬁcient to reduce PGC-1 ex-
pression levels, we used IL-1β or AV-IKK-β as NF-κB activating stimuli.
In C2C12 myotubes, both IL-1β stimulation and AV-IKK-β delivery, like
TNF-α, decreased PGC-1α and PGC-1βmRNA levels (Fig. 6f, g). Interest-
ingly, pre-treatment of differentiated C2C12myotubeswith a RNApoly-
merase inhibitor, actinomycin D, before TNF-α treatment abolished
TNF-α-induced reductions in PGC-1α mRNA (Fig. 6h) and PGC-1α-
regulated genes (MyHC I and Cox II) (Fig. S6A, B). Knock-down of
PGC-1α decreasedmRNA levels of MyHC I, OXPHOS sub-units and mito-
chondrial fusion and ﬁssion genes, recapitulating the effects of TNF-α
stimulation (Fig. S6C–E).Fig. 5. Classical NF-κB activation impairs the regulation of muscle oxidative phenotype a)
were stimulated with vehicle (bovine serum albumin; control) or TNF-α (10 ng/ml) for
SIRT-1 mRNA levels were determined by Q-PCR. Gene expression data were corrected by u
genes (cyclophilinA, β2-microglobuline, hypoxanthine-guanine phosphoribosyltransferase
siently transfected with either b) a Tfam promoter reporter construct or c) a NRF-1 trans
(PcDNA3.1) or plasmids encoding constitutive active IKK-β (c.a. IKK-β) or a kinase-dead
(10 ng/ml) or vehicle (bovine serum albumin). Twenty-four hours after transfection cells we
d) C2C12 myoblasts were transiently transfected with a general PPAR reporter plasmid. Simu
stitutive active IKK-β (c.a. IKK-β) or a kinase-dead IKK-β isoform (IKK-β KD) were co-t
albumin). Twenty-four hours after transfection cells were harvested. e, f) C2C12 myobl
reporter construct. Simultaneously, plasmids encoding empty vector (PcDNA3.1) or pla
trans-activation domains were co-transfected. Twenty-four hours post transfection, cells
activity. g) C2C12 myoblasts were transiently transfected with speciﬁc PPAR reporters and e
cells were treated with vehicle (bovine serum albumin; control) or TNF-α (10 ng/ml) for 24
β-galactosidase activity. Values are expressed as mean ± SD from triplicate samples (experim4. Discussion
In the present study, we unravelled amolecular mechanism underly-
ing the detrimental effects of TNF-α on skeletal muscle OXPHEN. A de-
tailed investigation of key markers and regulators of muscle OXPHEN
and a dissection of inﬂammatory signalling revealed that intact classical
NF-κB signalling is required for TNF-α-induced impairments in muscle
OXPHEN and that activation of classical NF-κB signalling is sufﬁcient to
impair multiple aspects of skeletal muscle OXPHEN. Furthermore, as a
potential underlyingmechanism, NF-κB activation proved to be required
and sufﬁcient for reducing PGC-1αmRNA expression levels in vitro and
in vivo and for disturbing PGC-1-co-activated signalling events that
signify key steps in OXPHEN regulation.
Interestingly, similar to our ﬁndings in skeletal muscle, TNF-α also
depresses mitochondrial function and content in other cell types. In
cardiac myocytes, reductions in expression levels of OXPHOS complex
I, decreases in ATP content and impairments in mitochondrial function
upon TNF-α exposure have been described in vitro and in vivo [39–41].
Furthermore, blockade of TNF-α proved to be sufﬁcient to ameliorate
cardiac mitochondrial dysfunction in a mouse model of experimental
heart failure [42]. In addition, in white and brown adipocytes, TNF-α
impaired mitochondrial biogenesis, decreased expression and activity
levels of constituents of fatty acid β-oxidation, the Krebs cycle as well
as OXPHOS events with a subsequent decrease in cellular ATP content
[43–45]. These ﬁndings imply that TNF-α-induced disturbances in
OXPHEN are not restricted to skeletal muscle and may involve a mech-
anism conserved within various tissues.
The molecular mechanisms by which TNF-α impairs mitochondrial
function however have not been properly addressed yet. In muscle,
we now convincingly show that classical NF-κB activation is required
for TNF-α-induced impairment of all constituents of cellular OXPHEN
that were examined. In line with our data, Cogswell et al., using
lymphoma and ﬁbrosarcoma cell lines, demonstrated that NF-κB
blockade prevented TNF-α-induced reductions in the expression
ofmitochondrial-encodedOXPHOS sub-units [46]. In addition to the re-
quirement of intact NF-κB signalling, we tested whether classical NF-κB
activation, in absence of inﬂammatory cytokines, was sufﬁcient to im-
pair cellular OXPHEN. To this end, we applied IL-1β rather than TNF-α
to myotube cultures as an alternative NF-κB activating stimulus.
Although TNF-α and IL-1β feed into the classical NF-κB pathway
via different receptors, classical NF-κB activation by both of these
inﬂammatory cytokines converges at the level of the IKK complex
[47]. Similar to TNF-α, when IL-1β was used, an impaired muscle
OXPHEN was observed. Consistent with these data, IL-1β was shown
to inhibit mitochondrial respiration and ATP synthesis in primary
hepatocytes and hepatocyte cell lines [48–50]. It has to be noted
however that the impact of IL-1β on muscle OXPHEN in our study
was less pronounced when compared to TNF-α, which may be due
to a smaller degree of NF-κB activation upon chronic stimulation in
our system. In addition to experiments with IL-1β or TNF-α as
NF-κB activators genetic activation of classical NF-κB by IKK-βWT C2C12 myoblasts were differentiated for 5 days into mature myotubes. Myotubes
72 h. PGC-1α, PGC-1β, PPAR-α, PPAR-δ, PPAR-γ, Tfam, NRF-1, NRF-2α, ERR-α and
sing a GeNorm normalisation factor calculated from the expression of 4 housekeeping
and glyceraldehyde-3-phosphate dehydrogenase). b, c) C2C12 myoblasts were tran-
criptional activity reporter plasmid. Simultaneously, plasmids encoding empty vector
IKK-β isoform (IKK-β KD) were co-transfected. Cells were stimulated with TNF-α
re lysed, luciferase activity was determined and normalised for β-galactosidase activity.
ltaneously, plasmids encoding empty vector (PcDNA3.1) or plasmids encoding con-
ransfected. Cells were stimulated with TNF-α (10 ng/ml) or vehicle (bovine serum
asts were transiently transfected with either a PPAR-α or a PPAR-γ transcriptional
smids encoding wild-type p65 or p65 with 1 (-534), 2 (-521) or 3 (-313) mutated
were lysed, luciferase activity was determined and normalised for β-galactosidase
mpty vector (PcDNA 3.1) or an IκBα-SR-expressing plasmid (SR). 24 h post-transfection
h. Subsequently, cells were lysed, luciferase activity was determined and normalised for
ents n = 3). Signiﬁcance compared to control: * p ≤ 0.05, # p ≤ 0.1.
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OXPHEN. Collectively, these data demonstrate that intact NF-κB signalling
is required for TNF-α-induced impairments in muscle OXPHEN and that
activation of classical NF-κB signalling is sufﬁcient for impairing structural
as well as enzymatic components of muscle OXPHEN.
Mitochondria are dynamic organelles that constantly undergo
fusion and ﬁssion. These opposing processes work in concert tomaintaina
c
e
gthe shape, size, and number ofmitochondria and their physiological func-
tion [51]. Interestingly, mitochondrial morphology appeared altered
upon TNF-α-induced NF-κB activation in our system, manifested by
swollen and less elongated organelles compared to vehicle-treated
myotubes. Similar effects on mitochondrial morphology have been ob-
served in adipocytes and cardiomyocytes chronically exposed to TNF-α
[40,44]. Altered mitochondrial morphology induced by TNF-α in ourb
d
f
h
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fusion and ﬁssion genes, a process that required intact NF-κB signalling.
Mitochondrial ﬁssion and fusion events have been implicated in the
process ofmitophagy, which is a quality control process inwhich tubular
networks ofmitochondria are degraded to segregate dysfunctionalmito-
chondria which are then selectively degraded by autophagy [51].
Whether or not inﬂammation may lead to mitophagy and how this
subsequently affects muscle OXPHEN requires further studies as no
data is present in the literature. On the other hand, it is well-known
that mitochondrial fusion and ﬁssion genes are under control of
PGC-1-co-activated signalling events, which is in line with our own
data. Therefore, the decrease in mitochondrial fusion and ﬁssion gene
expression upon TNF-α exposure might well just be a direct conse-
quence of the general decrease in mitochondrial protein expression
and impairments in the PGC-1 signalling cascade caused by classical
NF-κB activation.
The fact that all parameters of cellular OXPHENwere indiscriminately
down-regulated by inﬂammatory cytokine- and genetically-induced
classical NF-κB activation suggests that activation of the classical NF-κB
pathway impedes on the key regulatory pathways determining muscle
OXPHEN. PGC-1 molecules are essential co-activators of proteins in-
volved in the regulation of mitochondrial biogenesis (Tfam, NRF-1),
uptake and oxidation of substrates, expression of oxidative ﬁbres
(PPAR-α, PPAR-δ) and control of mitochondrial fusion and ﬁssion
events [19,52,53]. In our study, inﬂammatory cytokine-induced re-
ductions in expression and activity levels of mitochondrial proteins
were associated with decreased mRNA levels of both PGC-1α and
PGC-1β. In addition, TNF-α not only reduced PGC-1 isoform mRNA
expression itself but also potently inhibited PGC-1-co-actived signalling
events. These ﬁndings are consistent with observations in other cell
types as TNF-α-mediated reductions in PGC-1α expression levels
have been described in cardiomyocytes [54] and adipocytes [43]. Fur-
thermore, both our in vitro and in vivo data show that TNF-α-induced
decreases in PGC-1α mRNA expression depended on intact classical
NF-κB activation which is in coherence with our data on phenotypic
OXPHEN markers. Similarly, TNF-α-induced reductions in PGC-1α
mRNA expression in cardiac cells were shown to be attenuated by the
NF-κB inhibitor parthenolide [54]. On the other hand, activation of
classical NF-κB in our study (by over-expression of IKK-β) potently re-
duced PGC-1α and PGC-1β expression and impaired PGC-1-controlled
signalling events similar to TNF-αwhich was largely mediated through
IKK-β enzymatic activity. The observation that reductions in PGC-1α
expression in our study occurred rapidly after TNF-α stimulation and
temporally preceded changes in cellular OXPHEN suggest that reduc-
tions in PGC-1α expression and function underlie NF-κB-induced im-
pairments in muscle OXPHEN. Importantly, a swift reduction in
PGC-1α mRNA levels upon TNF-α exposure was conﬁrmed in vivo by
intra-muscular TNF-α injection. It is well described that muscle-speciﬁc
knock-out of PGC-1α impairs muscle OXPHEN in vivo [55,56] and
knock-down of PGC-1α in our system mimicked TNF-α-induced reduc-
tions in oxidative gene expression as well as mitochondrial ﬁssion and
fusion genes. Collectively, this body of data supports the notion that re-
ductions in PGC-1α expression and subsequent inhibition of PGC-1-
co-activated signalling events by activation of classical NF-κB mayFig. 6. Classical NF-κB activation reduces PGC-1 mRNA expression. a, b) Mouse primary myo
with vehicle (bovine serum albumin; control) or TNF-α (10 ng/ml) for the indicated times a
C2C12 or C2C12-IκBα-super-repressor (SR) myoblasts were differentiated for 5 days in diffe
(bovine serum albumin; control) or TNF-α (10 ng/ml) for the indicated times. PGC-1α
(muscle-speciﬁc expression of the IκBα-SR construct) mice received an intra-muscular (m.
sacriﬁced 7 h post-injection and PGC-1α and PGC-1β mRNA expression was evaluated by Q-
into fully mature myotubes. Myotubes were stimulated with vehicle (bovine serum albumin; c
dicated times (g). PGC-1α and PGC-1β mRNA expression were determined by Q-PCR. h) C2C
myotubes. Myotubes were subsequently pre-treated with actinomycin D (50 ng/ml) or vehic
TNF-α (10 ng/ml) for 24 h. PGC-1αmRNA levelswere determinedbyQ-PCR. Gene expressiond
of 4 housekeeping genes (cyclophilinA, β2-microglobuline, hypoxanthine-guanine phosphoribo
mean ± SD from triplicate samples (experiments n = 3). Signiﬁcance compared to control: *well underlie inﬂammation-induced impairments in cellular OXPHEN
and alterations in mitochondrial ﬁssion and fusion gene expression.
The exact mechanisms underlying reductions in PGC-1 expression and
function however remain to be elucidated.
Interestingly, Eisele et al. recently reported that PGC-1 molecules
inhibit activation of the classical NF-κB pathway [57]. This implies that
activation of the PGC-1 signalling cascademight not only improvemus-
cle OXPHEN directly butmay also alleviatemuscle inﬂammatory status.
Furthermore, the reciprocal interaction of these signalling pathways in
muscle may not only control muscle OXPHEN but may also apply to
muscle atrophy or dystrophy-associated damage which are both
induced by inﬂammation and prevented or attenuated by ectopic
PGC-1α expression [57].
Intriguingly, PGC-1α is present in the nucleus as well as in mito-
chondria and can bind to the genomes of both organelles [25,58]. In
addition, NF-κB constituents: (i.e. p65, the IKK proteins and IκBα)
have also been found to be present in mitochondria. Stimulation of
mitochondria with TNF-α subsequently resulted in activated NF-κB
signalling in these organelles (evidenced by IκBα degradation) and
reduced expression of mitochondrial-encoded OXPHOS sub-units [46].
As p65 has been shown to be able to physically bind to PGC-1α [59],
p65 may exert physical binding-mediated repression on PGC-1α-
co-activated signalling events, both in the nuclear and mitochondrial
compartment, thereby compromising adequate regulation of cellular
OXPHEN. Our ﬁnding that TNF-α decreases both nuclear-encoded and
mitochondrial-encoded OXPHOS sub-units is in line with this sugges-
tion. Several groups conﬁrmed p65 mitochondrial localisation and
recruitment to the mitochondrial genome where it repressed mito-
chondrial gene expression, oxygen consumption, and cellular ATP
levels [60,61]. Interestingly, it was also shown that trans-activation
domains of p65 were required for the p65-mediated decrease in ex-
pression levels of mitochondrial-encoded OXPHOS sub-units. In line
with this notion, in our study, intact p65 trans-activation domains
were required for p65-mediated inhibition of signalling events
known to be co-activated by PGC-1molecules. This suggests that active
transcription of a NF-κB target gene by P65 is required for inhibition of
PGC-1-mediated regulation of muscle OXPHEN by classical NF-κB sig-
nalling. This is in coherence with our data that blocking of de novo tran-
scription dissipates the inhibitory effect of TNF-α on PGC-1α transcript
levels and PGC-regulated gene expression. Although speculative in na-
ture, P65-mediated transcription of miRNA molecules encoded within
classical NF-κB target genes might be involved in PGC-1 inhibition
upon NF-κB activation. Recently, miR-696was shown to negatively reg-
ulate PGC-1α abundance in mouse skeletal muscle [62]. However, this
was shown to bemediated at the post-translational level bymodulation
of PGC-1α protein abundance. In addition, miR-23 was identiﬁed as a
putative negative regulator of muscle PGC-1α abundance [63]. It is
however unclear whether or not miR-696 and miR-23 are targets of
classical NF-κB signalling and if thesemolecules are involved in classical
NF-κB activation-induced repression of PGC-1-mediated signalling
events in the control of muscle OXPHEN. In addition, an NF-κB DNA
binding site was shown to be present within the PGC-1α promoter
[64] suggesting that modulation of PGC-1α transcript levels by classical
NF-κB activation might be mediated at the level of promoter activation.blasts were differentiated for 5 days into mature myotubes. Myotubes were stimulated
nd PGC-1α and PGC-1βmRNA levels were determined by Q-PCR. c, d) Wild-type (WT)
rentiation medium into fully mature myotubes. Myotubes were stimulated with vehicle
and PGC-1β mRNA levels were determined by Q-PCR. e) Wild-type (WT) or MISR
gastrocnemius) injection with NaCl (n = 3) or TNF-α (10 ng/ml) (n = 3). Mice were
PCR. f, g) WT C2C12 myoblasts were differentiated for 5 days in differentiation medium
ontrol) or IL-1β (10 ng/ml) (f) or infected with AV-GFP (control) or AV-IKK-β for the in-
12 myoblasts were differentiated for 5 days in differentiation medium into fully mature
le (DMSO) for 2 h after which myotubes were stimulated with vehicle (BSA; control) or
atawere corrected byusing a GeNormnormalisation factor calculated from the expression
syltransferase and glyceraldehyde-3-phosphate dehydrogenase). Values are expressed as
p ≤ 0.05, # p ≤ 0.01.
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Our ﬁndings uncover a new mechanism in which p65 (as part of
classical NF-κB signalling) impairs the regulation of skeletal muscle
OXPHEN under inﬂammatory conditions. The molecular mechanisms
by which classical NF-κB activation reduces PGC-1 transcript levels
and impairs PGC-1-mediated signalling events in muscle OXPHEN
regulation howeverwarrant further investigation. In this regard, it is in-
teresting to note that Guttridge et al. recently identiﬁed an important
role for IKK-α, as part of the alternative NF-κB pathway, in the regula-
tion of muscle OXPHEN by PGC-1 molecules [65]. Future research is
needed to unravel whether or not IKK-α-mediated control of muscle
OXPHEN is modulated by inﬂammation-induced classical NF-κB activa-
tion as a potential novel mechanism underlying inﬂammation-induced
impairments of muscle OXPHEN.
Collectively, this research is relevant for chronic diseases with
severe systemic consequences of (inﬂammation-induced) loss of muscle
OXPHEN, including COPD, CHF, T2DMand perhaps also cancer. In light of
our data, inhibition of chronic NF-κB activation in muscle may be desir-
able to improve muscle OXPHEN in these diseases. Novel inhibitors of
classical NF-κB are currently in development [66,67]. Recently, systemic
delivery of a NF-κB blocking peptide and genetic NF-κB blockade by
adenoviral delivery proved to be efﬁcient in attenuating muscle
NF-κB signalling and improved muscle function and muscle regenera-
tion in an mdx mouse model of muscular dystrophy (which is
characterised by chronic muscle inﬂammation) [66,67]. Future studies
are needed to establish whether blockade of classical NF-κB can restore
skeletal muscle OXPHEN in the context of chronic disorders associated
with a sustained low-grade inﬂammatory status.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.03.018.
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